Cover Image
市場調查報告書

嘔吐的開發中產品分析

Emesis (Vomiting) - Pipeline Review, H2 2015

出版商 Global Markets Direct 商品編碼 246019
出版日期 內容資訊 英文 36 Pages
訂單完成後即時交付
價格
Back to Top
嘔吐的開發中產品分析 Emesis (Vomiting) - Pipeline Review, H2 2015
出版日期: 2015年12月16日 內容資訊: 英文 36 Pages
簡介

噁心(醫療用語稱為「嘔吐」,一般則用各種用語來表示)是指胃內的東西強制由口(不同情況下有可能從鼻)排出。嘔吐會在種狀況下發生。具體舉例譬如胃炎等疾病或對毒物的特定反應、(腦朣瘤、頭蓋骨內壓上升、過剩曝曬於電離放射線下)各種疾病的一般性後遺症等。通常噁心會在嘔吐前發生,但卻不一定是必然有的連動反應。為了抑制噁心、嘔吐,就需要止吐劑。此外,如果產生脫水症狀的嚴重情況,就必須在靜脈打點滴。止吐劑一般用在治療容易暈車暈交通工具、Opioids(類鴉片物質)·化療時的副作用等。

本報告提供全球各國治療嘔吐用的開發中產品開發情形相關分析,彙整開發中產品的最新趨勢,及臨床實驗各階段產品一覽,再加上主要企業簡介,主要藥物概要(產品概要,功能機制,研究開發(R&D)的發展情形),最新的產業趨勢等調查,並將結果概述為以下內容。

簡介

  • 分析範圍

嘔吐概要

治療藥的開發

  • 嘔吐開發中產品:概要
  • 嘔吐開發中產品:比較分析

各企業開發中的嘔吐治療藥

大學/研究機關研究中的嘔吐治療藥

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品
  • 不明確的階段有的產品

嘔吐治療藥:開發中的產品的一覽(各企業)

嘔吐治療藥:研究中的產品的一覽(大學/研究機關別)

嘔吐治療藥的開發作的企業

  • Astellas Pharma Inc.
  • Charleston Laboratories, Inc.
  • Sparsha Pharma International Pvt. Ltd.
  • NanoForm Therapeutics Ltd.
  • Epiomed Therapeutics, Inc.

嘔吐:治療藥的評估

  • 單劑治療藥的情況
  • 標的別
  • 各行動機制
  • 各投藥法
  • 分子的各類型
  • 各治療分類

藥物簡介

  • CL-108
  • CLH-1-T
  • 5-HT3受體拮抗劑貼片
  • FK-886
  • ETI-385
  • 以TRIM-21為目標的抗體
  • aprepitant
  • CLBPC
  • CLFTC
  • CLHMC
  • CLOXC
  • CLHDC
  • CLH-5
  • CLH-10

嘔吐治療藥:最新的藥物簡介

嘔吐治療藥:暫停開發的產品

嘔吐治療藥:開發中止的產品

嘔吐相關產品的開發里程碑

  • 值得注意的最新趨勢·新聞稿(全4件)

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC7457IDB

Summary

Global Markets Direct's, 'Emesis (Vomiting) - Pipeline Review, H2 2015', provides an overview of the Emesis (Vomiting)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Emesis (Vomiting), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Emesis (Vomiting) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Emesis (Vomiting)
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Emesis (Vomiting) and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Emesis (Vomiting) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Emesis (Vomiting) pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Emesis (Vomiting)
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Emesis (Vomiting) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Emesis (Vomiting) Overview
  • Therapeutics Development
    • Pipeline Products for Emesis (Vomiting) - Overview
    • Pipeline Products for Emesis (Vomiting) - Comparative Analysis
  • Emesis (Vomiting) - Therapeutics under Development by Companies
  • Emesis (Vomiting) - Therapeutics under Investigation by Universities/Institutes
  • Emesis (Vomiting) - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Emesis (Vomiting) - Products under Development by Companies
  • Emesis (Vomiting) - Products under Investigation by Universities/Institutes
  • Emesis (Vomiting) - Companies Involved in Therapeutics Development
    • Daewoong Pharmaceutical Co., Ltd.
    • Epiomed Therapeutics, Inc.
    • InteguRx Therapeutics, LLC
  • Emesis (Vomiting) - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • Antibodies to Target TRIM-21 for Gastrointestinal and Ear Nose Throat Disorders - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • DWJ-1308 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ETI-385 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • granisetron hydrochloride SR - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NEO-1940 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ondansetron hydrochloride - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Emesis (Vomiting) - Dormant Projects
  • Emesis (Vomiting) - Discontinued Products
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Emesis (Vomiting), H2 2015
  • Number of Products under Development for Emesis (Vomiting) - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Investigation by Universities/Institutes, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Development, H2 2015
  • Products under Development by Companies, H2 2015
  • Products under Investigation by Universities/Institutes, H2 2015
  • Emesis (Vomiting) - Pipeline by Daewoong Pharmaceutical Co., Ltd., H2 2015
  • Emesis (Vomiting) - Pipeline by Epiomed Therapeutics, Inc., H2 2015
  • Emesis (Vomiting) - Pipeline by InteguRx Therapeutics, LLC, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Stage and Target, H2 2015
  • Number of Products by Stage and Mechanism of Action, H2 2015
  • Number of Products by Stage and Route of Administration, H2 2015
  • Number of Products by Stage and Molecule Type, H2 2015
  • Emesis (Vomiting) - Dormant Projects, H2 2015
  • Emesis (Vomiting) - Discontinued Products, H2 2015

List of Figures

  • Number of Products under Development for Emesis (Vomiting), H2 2015
  • Number of Products under Development for Emesis (Vomiting) - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Investigation by Universities/Institutes, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Products, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Targets, H2 2015
  • Number of Products by Stage and Targets, H2 2015
  • Number of Products by Mechanism of Actions, H2 2015
  • Number of Products by Stage and Mechanism of Actions, H2 2015
  • Number of Products by Routes of Administration, H2 2015
  • Number of Products by Stage and Routes of Administration, H2 2015
  • Number of Products by Molecule Types, H2 2015
  • Number of Products by Stage and Molecule Types, H2 2015
Back to Top